BF
Biofrontera Inc.
BFRI · NASDAQ
$1.02 -2.40% (-$0.03)
1M -35.26%
Market Cap $13.0M
P/E Ratio -
Div. Yield -
ROE 127.78%
Bulios Fair Price
$1.45
42.9% upside
Current Price
$1.02
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BFRI is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Weak
2/9Valuation
92 /100
Cheap P/B 2.18x
P/S 0.28x
P/FFO N/A
Growth
62 /100
Stable Book val. growth 24.00%
Rev. growth 13.30%
FCF growth N/A
Profitability
20 /100
Weak Op. margin 9.45%
Gross margin 84.45%
FCF margin 17.17%
Quality
15 /100
Poor ROA 26.45%
ROIC 31.33%
Asset turnover 1.92x
Debt
31 /100
High Int. coverage -26.91x
Debt/Equity 1.26x
Current ratio 1.18x
Stability
56 /100
Moderate EPS volatility 1,217.10%
Beta 0.84x
Profitable years 0
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BFRI
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Hermann Lübbert
Employees
89
Headquarters
Woburn
Upcoming events
11 NOV
Earnings
Upcoming earnings report